Promising Outcomes from First-in-Human Trial of DLL3-Targeted Antibody-Drug Conjugate SHR-4849 in Relapsed Small Cell Lung Cancer
First-in-Human Trial Highlights Breakthrough DLL3-Targeted Therapy for Relapsed Small Cell Lung Cancer In a landmark development in the treatment of ...
